Option Care Health, Inc.

Option Care Health, Inc. (NASDAQ:OPCH) is the largest provider of home and alternate site infusion services in the United States. Founded in 1996 and headquartered in Bannockburn, Illinois, the company has grown through organic expansion and strategic acquisitions to become a national leader in specialized healthcare delivery. Option Care Health operates a comprehensive network of compounding pharmacies, infusion suites, and clinical services that enable patients to receive complex medical treatments in their homes or convenient outpatient settings rather than traditional hospital environments.

Over the past few years, Option Care Health has pursued several key strategic initiatives focused on expanding its service delivery capabilities and diversifying its therapeutic portfolio. The company has significantly expanded its ambulatory infusion suite network, growing from approximately 150 locations to over 175 sites with more than 750 infusion chairs. This expansion represents a strategic shift toward providing patients with convenient outpatient alternatives to home-based care, while improving nurse productivity by up to 20% in mature locations. The company has made substantial technology investments, including AI-embedded intelligence in patient registration processes and robotic process automation in revenue cycle management. These initiatives aim to improve operational efficiency and reduce administrative costs. Option Care Health also launched the TouchPoint mobile app for enhanced patient engagement and acquired Specialty Pharmacy Nursing Network to expand its clinical capabilities. Strategic acquisitions have been a consistent focus, with the most recent being Intramed Plus in the Southeast region for $117 million in early 2025. The company has maintained a disciplined approach to M&A, focusing on complementary businesses that enhance geographic coverage or clinical capabilities rather than pursuing large transformational deals. The company has increasingly emphasized rare and orphan therapies as a growth driver, recognizing these treatments typically offer better margins and more stable reimbursement compared to more commoditized acute therapies. This strategic focus has contributed to strong growth in the chronic therapy portfolio, which now represents approximately 75% of total revenue. Capital allocation has balanced growth investments with shareholder returns. The company has repurchased over $100 million in stock during 2024 and early 2025 while maintaining financial flexibility for acquisitions. Management has also invested in expanding compounding pharmacy capabilities, opening new state-of-the-art facilities in New York City and Tampa to support growing demand for complex sterile preparations.